ATHYRIUM - Key Persons
Andrew Hyman - Chief Legal Officer, COO
Ms. Pun joined Athyrium in 2018 and currently serves as a Vice President.
Prior to joining Athyrium, Ms. Pun was an investment banking analyst in the Global Healthcare group at Bank of America Merrill Lynch. In that role, Ms. Pun focused on M&A, public and private capital raising, licensing deals, and a wide scope of advisory work for biotechnology and pharmaceutical companies.
Ms. Pun graduated with a B.S.E. in Biomedical Engineering with a minor in Finance from Duke University in 2016.
Ms. Ruan joined Athyrium in 2023 and currently serves as an Associate.
Prior to joining Athyrium, Ms. Ruan was an investment banking analyst in the Healthcare group at PJT Partners. While at PJT, Ms. Ruan focused on M&A, partnerships and advisory services for biotechnology and large cap pharmaceutical companies.
Ms. Ruan graduated with a B.S. in Economics and B.A. in Biology from the University of Pennsylvania in 2021.
Job Titles:
- Senior Business Support Specialist
Mr. Hayes joined Athyrium in 2023 and currently serves as an Associate.
Prior to joining Athyrium, Mr. Hayes was an investment banking analyst at Lazard where he focused on Healthcare M&A.
Mr. Hayes graduated with a B.B.A. in Finance and a minor in History from the University of Notre Dame in 2020.
Job Titles:
- VP, Investor Relations and Associate General Counsel
Job Titles:
- Senior Advisor
- Founder and Managing Director of DHL Ventures LLC
- Senior Member of the Healthcare Team at Commenda Capital
Mr. Lee is a senior member of the healthcare team at Commenda Capital, an Atlanta, Georgia-based merchant bank and consultancy that provides creative, bespoke solutions that span capital formation, corporate strategy and operational support to maximize value to companies and investors.
Mr. Lee is also the Founder and Managing Director of DHL Ventures LLC, a financial and strategic advisory firm based in Boston, Massachusetts. Mr. Lee has been providing consulting services to Athyrium funds since 2012. Mr. Lee has more than 22 years of experience in life sciences investments across therapeutics, devices, diagnostics and services / HCIT as an investment banker, venture capitalist, entrepreneur and hedge fund analyst. Mr. Lee specializes in structuring and implementing creative and complex deal structures and working closely with management teams on financing and exit strategies.
Prior to founding DHL Ventures, Mr. Lee was a Senior Analyst with Burrage Capital, a life sciences focused long-short equity fund. Previously, Mr. Lee was the Chief Financial and Corporate Development Officer at Talaris Advisors, a biotech accelerator that leverages a strategic drug development discipline to minimize risk and cost while optimizing the odds of success in drug development portfolios.
Before founding Talaris Advisors, Mr. Lee was a Principal with SV Life Sciences (SVLS), a leading healthcare focused venture capital advisor with approximately $2B under management. For close to a decade at SVLS, Mr. Lee was actively involved with more than 55 portfolio companies across biotechnology, medical devices and healthcare services investments. He worked closely with management teams across a range of issues including equity and debt financings, M&A, IPOs, partnerships and exits.
As an investment banker, Mr. Lee was with the Global Healthcare Group at UBS Warburg where he engaged in a variety of equity and M&A transactions in the life sciences sector. Prior to joining UBS Warburg, Mr. Lee was in the Healthcare Investment Banking Group at Salomon Smith Barney. Mr. Lee received his BS in Finance from Bentley College.
Job Titles:
- Senior Business Support Specialist
Ms. Singh joined Athyrium in 2018 and currently serves as a Senior Business Support Specialist.
Prior to joining Athyrium, Ms. Singh spent nearly ten years at Soros Fund Management. While at Soros, her time was focused on managing processes and functions for C-level executives as well as firmwide technology projects and initiatives. Ms. Singh began her career as a consultant at Goldman Sachs where she worked closely with bankers worldwide in presentation coordination.
Ms. Singh graduated with a B.S. in Telecommunications, with a minor in Business, from St. John's University and holds an MBA in Project Management from the Keller Graduate School of Management.
Job Titles:
- Senior Vice President, Finance
Ms. Strong joined Athyrium in 2016 and currently serves as Senior Vice President, Finance.
Prior to joining Athyrium, Ms. Strong was a Vice President at JPMorgan Chase & Co. where she worked as a Fund Controller for the Global Access Portfolios, covering both hedge fund-of-funds and multi-asset vehicles.
Before joining J.P. Morgan, Ms. Strong was a Vice President at Goldman Sachs & Co, where she worked as a Fund Controller from 2005 to 2013, supporting the Goldman Sachs Private Equity Group. Ms. Strong began her career with Arthur Andersen in Norway.
Ms. Strong graduated with a degree in Economics and Business Administration, specializing in Finance, from the Norwegian School of Economics in 2001.
Ms. Au joined Athyrium in 2018 and currently serves as Vice President, Finance.
Prior to joining Athyrium, Ms. Au was at Och-Ziff Capital Management where she was responsible for financial and regulatory reporting functions.
Before Och-Ziff Capital, Ms. Au was an Advisory Manager at KPMG LLP specializing in Alternative Investment clients. Prior to that, Ms. Au was a Controller at Fortress Investment Group Liquid Market Division.
Ms. Au received a B.A. in Economics from the University of Western Ontario, Canada.
Mr. Hsu joined Athyrium in 2021 and currently serves as Controller.
Prior to joining Athyrium, Mr. Hsu was a Controller at Sculptor Capital Management where he was responsible for fund accounting and financial reporting functions. Prior to that, Mr. Hsu was a Senior Manager in the Audit and Assurance practice group at EisnerAmper LLP, primarily servicing financial services clients and SEC registrants.
Mr. Hsu received a B.B.A. in Finance from University of Kentucky and a M.S. in Accounting from City University of New York at Baruch College. Mr. Hsu is a CPA certified in the State of New York.
Mr. Ferrell founded Athyrium in 2008 and currently serves as the firm's Managing Partner. Mr. Ferrell has substantial investment experience in the life sciences sector across a wide range of asset classes and transaction structures.
Prior to forming Athyrium, Mr. Ferrell served in a number of capacities at Lehman Brothers from 2001 to 2008. Most recently he oversaw life sciences investments for Global Trading Strategies, a principal investment group within Lehman. The $400 million portfolio was invested in equity, debt and structured investments of both public and private companies. Representative investments include: Sequenom, Bioenvision (acquired by Genzyme), Jazz Pharmaceuticals, Orthovita (acquired by Stryker), Nektar Therapeutics, ISTA Pharmaceuticals, and Lpath.
Prior to joining Global Trading, Mr. Ferrell was a Vice President in Lehman Brothers' Private Equity division focused on life sciences investments. Investments that Mr. Ferrell worked on include: Auxilium Pharmaceuticals, Jazz Pharmaceuticals, KaloBios, and Fluidigm.
Prior to joining Lehman in 2001, he was a Principal at Schroder Ventures Life Sciences (SVLS) based in Boston. While at Schroder, investments Mr. Ferrell was involved with include: EyeTech Pharmaceuticals, Versicor/Vicuron, Achillion, Allos Therapeutics, and GelTex Pharmaceuticals.
Mr. Ferrell graduated with an A.B. in Biochemical Sciences from Harvard College. Mr. Ferrell currently serves on the Board of Directors of Progenity.
Job Titles:
- Senior Advisor
- Executive Chairman of Sentry Data Systems
Mr. Randazzo has spent more than 35 years in the health care and technology fields. He brings vast experience in executive leadership to his role as a Senior Advisor to Athyrium. He has been a serial entrepreneur, having founded or led over a half dozen companies to successful exits.
In addition to supporting Athyrium, Mr. Randazzo currently serves as Executive Chairman of Sentry Data Systems, a provider of pharmacy technology solutions to hospitals, and Chairman of Complex Care Solutions, a high-touch care management company. Mr. Randazzo helped lead both of these organizations prior to their sales. Mr. Randazzo also serves as Executive Chairman of Water's Edge Dermatology, Chairman of Docutap (a Warburg Pincus portfolio company), and a board member of IMC, a Medicare-focused medical group based in Miami. He also co-founded FastMed where he served as CEO for 3 years before becoming Executive Chairman. Fastmed was the second largest independent urgent care network in the United States. Prior to FastMed, Mr. Randazzo was CEO of Touchstone Health Care, a managed Medicare company with more than $100 million in revenue, and served as CEO of BenefitPoint, an employee benefits technology firm now part of Vertifore. His executive experience also includes being President and CEO of Women's Health Connecticut, Inc., a services-based physician practice management and infertility organization, and President and CEO of Value Oncology Science, a specialty health care provider. Mr. Randazzo was a Co-Founder of Value Health Inc., and oversaw the firm's acquisitions and product development. At Managed Health Network, a behavioral health company that he co-founded and is now owned by Health Net, Mr. Randazzo served as COO and CFO. He is currently an advisor to Warburg Pincus.
Earlier in his career, Mr. Randazzo held positions at CIGNA where he was responsible for product development, healthcare insurance acquisitions and technology investments. Mr. Randazzo earned an MA in economics from the University of Texas and an MIA in international business from Columbia University. He holds a BA in economics and political science from the State University of New York.
Mr. Del Vecchio joined Athyrium in 2016 and currently serves as Controller.
Prior to joining Athyrium, Mr. Del Vecchio was a Vice President at OWS Capital Management, where he was responsible for the accounting, finance, and compliance functions. Prior to that, Mr. Del Vecchio was an Associate at GlobeOp Financial Services, where he delivered administrative support to hedge fund and private equity clients. In that capacity, he managed all fund accounting and operational functions.
Mr. Del Vecchio attended Union College and received a B.A. in Economics from the State University of New York at Purchase College.
Mr. Mack joined Athyrium in 2021 and currently serves as a Senior Associate.
Prior to joining Athyrium, Mr. Mack was an investment banking associate in the Healthcare Group at Nomura Securities. While at Nomura, Mr. Mack worked on a number of transactions involving M&A, equity and debt offerings for biotechnology, pharmaceutical and healthcare services companies.
Mr. Mack graduated with a B.A. in Cognitive Neuroscience with minors in the Biological Basis of Behavior and Japanese from the University of Pennsylvania in 2016. Mr. Mack earned an M.A. in Biotechnology from Columbia University.
Mr. Kavulich joined Athyrium in 2017 and currently serves as a Partner. He previously served as a Principal and as a Vice President. Since joining Athyrium, Mr. Kavulich has been actively involved with numerous investments, including growth equity and private equity style investments, fixed income and special situations. He participates in all major investment functions including origination, transaction execution, portfolio company development, and monetization events.
Mr. Kavulich has experience in both private and public market investing across the U.S. and Europe. His sub-sector experience includes specialty and OTC pharmaceuticals, pharma services, medical devices, healthcare services, and healthcare IT.
Prior to joining Athyrium, Mr. Kavulich was a Vice President at Avista Capital Partners, a middle market private equity firm, where he primarily focused on investments in the Healthcare industry, including leveraged buyouts, mergers, acquisitions, and growth equity investments. He formerly served as an Associate at Avista.
Prior to Avista, Mr. Kavulich served as an Analyst in the financial sponsors and leveraged finance groups at Morgan Stanley.
Mr. Kavulich received a B.S. in Foreign Service with a concentration in International Economics, Finance and Commerce and proficiency in Chinese from Georgetown University.
Mr. O'Brien joined Athyrium in 2018 and currently serves as a Vice President.
Prior to joining Athyrium, Mr. O'Brien was an investment banking analyst in the Healthcare group at Guggenheim Partners. While at Guggenheim, Mr. O'Brien worked on a number of transactions involving M&A and equity offerings for biotechnology and pharmaceutical companies.
Mr. O'Brien graduated with a B.S. in Economics, with concentrations in Finance and Accounting, from the University of Pennsylvania's Wharton School in 2016.
Job Titles:
- Principal
- Jordan - Principal
Ms. Fang Jordan joined Athyrium in 2015 and currently serves as a Principal. Ms. Fang Jordan is responsible for all aspects of the investment process from sourcing, due diligence, deal execution, monitoring to exit strategy. Ms. Fang Jordan has played a key role in the firm's structured credit and equity investments in specialty therapeutics and payor and provider technology and services.
Previously, she was an Associate Consultant at L.E.K. Consulting where she performed commercial due diligence and strategy projects for healthcare companies and private equity investors.
She graduated magna cum laude from the University of Pennsylvania with a B.A. in Health and Societies with a concentration in health care economics and a minor in Biology.
Mr. Kampa joined Athyrium in 2021 and currently serves as a Senior Associate.
Prior to joining Athyrium, Mr. Kampa was an investment banking analyst in the Restructuring Group at Guggenheim Securities. While at Guggenheim, Mr. Kampa worked on a variety of in-court and out-of-court restructuring transactions within the pharmaceutical industry.
Mr. Kampa graduated with a B.S.M in Finance with a minor in Economics from Tulane University's Freeman School of Business in 2019.
Job Titles:
- Senior Advisor
- Chairman at Acacia Pharma Group Plc
Dr. Vink began working with Athyrium in 2019 as a Senior Advisor. He is a seasoned senior executive working in the pharmaceutical industry for more than 30 years.
Dr. Vink serves as Chairman at Acacia Pharma Group Plc (EBR: ACPH) and Targovax ASA (TRVX-NO), both publicly listed biopharma companies based in the UK and Norway. Dr. Vink also serves as Chairman of VC-backed NMD Pharma, a neurology biopharma company in Denmark and is a board member at Santhera AG (SWX:SANN) and Spero Therapeutics (Nasdaq:SPRO). While serving at these companies, Dr. Vink has been involved in initial public listings, geographic expansions and achieving meaningful development and commercial milestones.
Previously, Dr. Vink served as Executive Vice-President and Chief Operating Officer at Cubist Inc., a leader in the anti-infective and acute care hospital market. He oversaw all worldwide commercial and technical operations as well as managing the company's P&L until the successful acquisition of Cubist by Merck. He joined Cubist in 2012 as Senior Vice President and Head of International Business Operations.
Prior to joining Cubist, he served as Senior Vice President, Global Head of Hospital Business and Biologics for Mylan Inc. In this role, he managed the global hospital business of the company. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of Novartis, Vice President International Business for Biogen, and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo.
Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.
Job Titles:
- Chief Financial Officer
- Fellow of the Financial Services Institute
Paul A. Wakefield currently serves as the firm's Chief Financial Officer.
Prior to joining Athyrium, Mr. Wakefield was the CFO for the Alternative Investments Division of Neuberger Berman. With an AUM of $ 20bn, Mr. Wakefield covered all fund classes including: Private Equity Funds, Hedge Funds, Mutual Funds and Hybrid Structures. Previously, Mr. Wakefield was the CAO for the Lehman Brothers Global Controller, before moving to the Hedge Fund Group. Prior to joining Lehman, Mr. Wakefield was an M&A Consultant, Hedge Fund Controller and completed extensive special projects for Credit Suisse and BNP Paribas.
Mr. Wakefield commenced his career with PricewaterhouseCoopers in Australia. At Horwath & Horwath International public accounting firm, he founded the Asset Management Practice, providing financial services for High Net Worth individuals and long term strategic planning.
Earning his BA in Accounting from The University of South Australia, Mr. Wakefield is a Fellow of the Financial Services Institute, a CPA, has graduate degrees in Applied Finance and Investment and is a Fellow of the Institute of Chartered Accountants.
Job Titles:
- Senior Counsel
- Vice President
Mr. Helfaer joined Athyrium in 2013 and currently serves as a Principal.
Prior to joining Athyrium, Mr. Helfaer was an investment banking analyst in the Global Healthcare group at Bank of America Merrill Lynch. In that capacity, Mr. Helfaer worked on a number of transactions involving leveraged buyouts, acquisitions, refinancings, initial public offerings and other debt and equity offerings across various healthcare verticals.
Mr. Helfaer graduated with a B.S. in Physics from Yale College in 2012.
Job Titles:
- Managing Director of Neuberger Berman
- Managing Director, Neuberger Berman Group
Samuel N. Porat is a Managing Director of Neuberger Berman and is a member of the Fund's Investment Committee. Mr. Porat serves as Head of Royalty and Alternative Income Investments at Neuberger Berman and in that capacity he is responsible for all Neuberger Berman-led operations and activities related to Athyrium investments. Additionally, he is a Co-Founder and member of the Board of Managers for Marquee Brands, a strategy focused on acquiring brand royalties and licensing. Prior to joining NB Alternatives in 2004, Mr. Porat worked in Lehman Brothers' Investment Banking Division in New York from 1997-1999 where he focused on corporate financings and strategic advisory across several industries. In addition, Mr. Porat was the Director of Strategic Planning at a venture-backed startup company based in New York from 1999-2001. Mr. Porat holds an M.B.A. (with honors) from the Wharton School of the University of Pennsylvania and a B.A. (with distinction) from Yale University.
Mr. Kumar joined Athyrium in 2023 and currently serves as an Associate.
Prior to joining Athyrium, Mr. Kumar was an investment banking analyst in the Health Care group at Truist Securities. While at Truist Securities, Mr. Kumar worked on a number of transactions involving M&A and debt offerings for healthcare services and HCIT companies.
Mr. Kumar graduated with a B.S. in Industrial Engineering with a concentration of Economic & Financial Systems from Georgia Institute of Technology in 2021.
Job Titles:
- Senior Advisor
- Advisor to NASA 's Translational Research Institute for Space Health
Seth Feuerstein, MD, JD, serves as a Senior Advisor for Athyrium. Dr. Feuerstein has spent more than 25 years in healthcare and is a seasoned healthcare executive and entrepreneur. He has worked across every stage from startup, scale, acquisition and large corporate management. He has worked to develop, study and scale technologically-based innovations to enhance access, data collection, research and care in the medical ecosystem. Most recently he was Chief Innovation Officer and Chief Medical Officer at Magellan Health, a $7 billion health insurance company working in Medicaid/Medicare, PBM, Radiology, Cardiology and Behavioral Benefit Management.
Dr. Feuerstein is considered to be a global leader in the field of digital health, healthcare innovation and other related fields including addiction care and suicide prevention.
Dr. Feuerstein also serves as an advisor to NASA's Translational Research Institute for Space Health, on the part time faculty at the Yale School of Medicine, as the Director of the Yale Center for Digital Health, on the advisory board of the Yale Center for Biomedical and Interventional Technology, and as a psychiatrist for the Connecticut Department of Mental Health and Addiction Services. Dr. Feuerstein is actively involved in the community, having launched Little Wonder, a non-profit organization that supports cancer patients and their loved ones by leveraging technology to improve their treatment experience with positive non-treatment related events to drive improved personal and clinical outcomes. The program is currently working with 20 cancer centers.
Dr. Feuerstein received his bachelor's degree from Cornell University, his medical and law degrees from New York University, and completed his medical internship and residency at Yale University.
Mr. Perry joined Athyrium in 2021 and currently serves as a Senior Associate.
Prior to joining Athyrium, Mr. Perry was an investment banking analyst in the Health Care group at Raymond James. While at Raymond James, Mr. Perry focused on M&A transactions for healthcare services companies.
Mr. Perry graduated with a B.B.A. in Finance with a minor in Statistics from the University of Georgia in 2017.